Study end-points
The primary study endpoint was TR progression (TR grade ≥3) and/or abnormal TRPG levels (PG >30 mmHg). The secondary study end-points were late-onset atrial fibrillation, HF hospitalization, sudden death or ventricular tachyarrhythmias, cardiovascular mortality, and all-cause mortality.